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Abstract: Liver stiffness (LS) assessed using transient elastography
(TE) can assess the risk of developing hepatocellular carcinoma (HCC).
We evaluated whether TE, when compared with histological data as a
reference standard, can predict the risk of HCC development in chronic
hepatitis B (CHB) patients starting antiviral therapy.
Observational cohort database of 381 patients with CHB who
underwent liver biopsy (LB) and TE were reviewed. All patients
underwent surveillance for HCC development using ultrasonography
and alpha-fetoprotein.
During the median follow-up period of 48.1 (interquartile range
30.3–69.3) months, HCC developed in 34 (8.9%) patients. In patients
with HCC development, age, proportion of diabetes mellitus, histologi-
cal fibrosis stage, and LS value were significantly higher than those in
patients without (all P<0.05). The cumulative incidence rates of HCCg Up Kim, MD, Ph e Kim, MD, PhD,
, MD, and Young Seok Kim, MD, PhD
groups (F0–2, F3, and F4; log-rank test, P<0.001). On multivariate
analysis, along with age, LS value was an independent predictor of HCC
development (hazard ratio 1.041, P<0.001), whereas histological sta-
ging was not (P>0.05).
TE predicted HCC development independently in patients with
CHB starting antiviral therapy. However, further investigation is needed
to determine whether the current surveillance strategy can be optimized
based on the LS value at the time of starting antiviral therapy.
(Medicine 95(12):e2985)
Abbreviations: ALT = alanine aminotransferase, AST = aspartate
aminotransferase, AUC = area under the receiver operating
characteristic curve, CHB = chronic hepatitis B, CI = confidence
interval, HBeAg = hepatitis B e antigen, HBV = hepatitis B virus,
HCC = hepatocellular carcinoma, HR = hazard ratio, IQR =
interquartile range, kPa = kilopascal, LB = liver biopsy, LRE =
liver-related event, LS = liver stiffness, ROC = receiver operating
characteristic, TE = transient elastography, ULN = upper limit of
normal, VR = virological response.
INTRODUCTION
C hronic hepatitis B virus (HBV) infection is a major cause ofliver cirrhosis and hepatocellular carcinoma (HCC) world-
wide, with more than 350 million people affected.1 During the
last several decades, the development of antiviral agents has
been a major breakthrough in the treatment of chronic hepatitis
B (CHB). Their use in CHB has prevented disease progression
and reduced the risk of HCC development.2,3 Although first-
generation nucleos (t)ides analogs such as lamivudine have
encouraged resistant HBV strain, more effective and less resist-
ance-prone antiviral agents, such as entecavir and tenofovir,
have been available recently. These newer agents suppress HBV
completely and promptly in CHB patients regardless of high
baseline viral load or the presence of drug resistance.4,5 Never-
theless, a low, but clinically relevant risk of HCC development
has still remained in CHB patients receiving antiviral therapy.6
In this era of potent antiviral therapy, the prognostic sig-
nificance of serum HBV DNA level, which was considered a risk
factor for HCC development, has substantially diminished. Thus,
it can be hypothesized that fibrotic burden that is significantly
related to the risk of developing HCC7,8 can stratify individual
patients into different risks of developing HCC among CHB
patients starting antiviral therapy. For evaluating the extent of
liver fibrosis, liver biopsy (LB) remains the gold standard to date.
However, due to the limitations of LB such as invasiveness,
sampling error, and inter- and intraobserver variability, LB is
often considered an ‘‘imperfect’’ surrogate marker for liverrial LBs are not feasible during antiviral
ice.9 Thus, to overcome the pitfalls of LB,
assess liver fibrosis have been developed.
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Transient elastography (TE) is one of the most widely
validated noninvasive tools for assessing fibrotic burden.10,11
The prognostic value of liver stiffness (LS) as measured by
TE in predicting critical events related to fibrosis pro-
gression, including the development of portal hypertension-
related complications and HCC, has been well established in
several longitudinal studies.12–15 Moreover, recent studies
demonstrated that TE can predict HCC or liver-related events
(LREs) even in patients receiving antiviral therapy.16–18
Although a recent study demonstrated that TE is more useful
in predicting LREs when compared with histological data in
CHB patients before starting antiviral therapy,19 further
validation of TE in predicting HCC in the era of antiviral
therapy is still required.
In this multicenter, retrospective study, we aimed to
evaluate the prognostic value of TE in predicting risk of
developing HCC as compared with the prognostic value of
histological data in CHB patients starting antiviral therapy.
METHODS
Patients
From November 2005 to January 2015, 465 CHB patients
who underwent LB and TE before starting antiviral therapy at 3
tertiary centers were considered for inclusion. The indication
for LB was the assessment of the severity of liver fibrosis and
inflammation before starting antiviral therapy. CHB was
defined as the persistent presence of serum hepatitis B surface
antigen for >6 months.17 Antiviral therapy was initiated in
accordance with the treatment guidelines of the Korean Associ-
ation for the Study of the Liver20 and reimbursement guidelines
of the National Health Insurance Service in Korea. Virological
response (VR) was defined as a reduction in HBVDNA levels to
<2000 IU/mL.
Exclusion criteria were as follows: failure to obtain reliable
LS values (valid shot¼ 0), an invalid LS value, delay between
LB and TE>1 month, starting antiviral therapy more than
1 month after LB, presence of HCC at enrollment or history
of it, HCC development within 6 month after enrollment,
history of previous antiviral therapy, history of decompensated
cirrhosis, Child–Pugh class B or C cirrhosis at enrollment,
unsuitable quality of LB specimen for appropriate interpret-
ation, coinfection with hepatitis C, hepatitis D, or HIV, right-
sided heart failure, pregnancy, and loss to follow-up (Supple-
mentary Figure 1, http://links.lww.com/MD/A759).
The study protocol conformed with the ethical guidelines
of the 1975 Declaration of Helsinki and was approved by the
Institutional Review Board of Severance Hospital as well as
other institutes. Written informed consents were not required
due to the retrospective nature of this study.
LB Examination
LB specimens were prepared with hematoxylin and eosin
(H&E) and Masson trichrome. All liver tissue samples were
evaluated by experienced pathologists at each center who was
blinded to the clinical data. The degree of liver histology was
evaluated semiquantitatively according to the Batts and Ludwig
scoring system.21 Fibrosis was staged as follows: F0, no fibro-
sis; F1, portal fibrosis without septa; F2, portal fibrosis and a
few septa; F3, numerous septa without cirrhosis; and F4,
Seo et alcirrhosis. The necro-inflammatory activity was graded as A0,
none; A1, minimal; A2, mild; A3, moderate; and A4,
severe activity.
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TE was performed as previously reported,15,22,23 and LS
value was expressed as kilopascal (kPa). In this study, only
LS values with at least 10 validated measurements and a
success rate of at least 60%, and an interquartile range (IQR)
to median value ratio (IQR/M) of <0.3 were considered
reliable.
Baseline Work-Up and Follow-Up
The baseline visit for enrollment was defined as the visit
during which LB was performed. At baseline and during
follow-up, all patient data were evaluated based on ultrasono-
graphy and laboratory work-up, including alpha-fetoprotein
every 3 or 6 months for screening of HCC and other portal
hypertension-related complications. The diagnosis of HCC
was established based on the guideline of the American
Association for the Study of Liver Disease.24 LRE was defined
as hepatic decompensation (variceal bleeding, ascites, spon-
taneous bacterial peritonitis, hepatic encephalopathy, or hepa-
torenal syndrome), HCC, and liver-related death. To avoid
statistical repetition, we selected the earliest LRE if a given
patient experienced different types of LRE at different
time points.
Statistical Analysis
Data are expressed as the median with range, the
meanSD, or number (n, %) as appropriate. Differences
among continuous and categorical variables were examined
using Student t test (or the Mann–Whitney test) and the
x2 test (or Fisher exact test), respectively. To assess the accuracy
of LS value in diagnosing histological bridging fibrosis and
cirrhosis, the receiver operating characteristics (ROC) curve and
its 95% confidence interval (CI) were calculated.23
The cumulative incidence rates of HCC and LRE were
analyzed using the Kaplan–Meier method with comparison
using the log-rank test. Times to HCC and LRE development
were calculated from the date of enrollment to the date of
development of HCC and the first LRE or the last follow-up. To
identify independent risk factors for developing HCC and LRE,
Cox proportional hazards regression analysis was used.23 Stat-
istical analyses were performed using SPSS software (version
18.0; SPSS Inc., Chicago, IL). A P value<0.05 was considered
statistically significant.
RESULTS
Patient Characteristics
After excluding 84 patients according to our exclusion
criteria, a total of 381 patients were finally selected for the
statistical analysis (Supplementary Figure 1, http://links.lww.
com/MD/A759). The baseline clinical characteristics of the
study population are described in Table 1. The mean age
was 44.1 years, and male sex was predominant (n¼ 251,
65.9%). The mean LS value and ALT level were 13.9 kPa
and 132.6 IU/L, respectively. The histological fibrosis stages
were F0–1 in 44 (11.5%) patients, F2 in 93 (24.4), F3 in 94
(24.7), and F4 in 150 (39.4).
A total of 344 (90.3%) patients were treated with nucleos
(t)ide analogs (67 with lamivudine, 21 with clevudine, 59 with
Medicine  Volume 95, Number 12, March 2016telbivudine, 9 with adefovir, 10 with tenofovir, and 178 with
entecavir), and 37 (9.7%) patients were treated with pegylated-
interferon.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. Baseline Characteristics of the Study Population
(n¼381)
Variables Values
Demographic variables
Age (yr) 44.1 12.3
Male sex 251 (65.9)
Body mass index (kg/m2) 23.6 2.9
Hypertension 43 (11.3)
Diabetes mellitus 31 (8.1)
Clinical cirrhosis 75 (19.7)
Laboratory variables
Alanine aminotransferase (IU/L) 132.6 206.9
Serum albumin (g/dL) 4.1 0.4
Total bilirubin (mg/dL) 0.85 0.69
HBeAg positivity 242 (63.5)
Log10 HBV DNA (IU/mL) 6.15 1.66
Platelet count (109/L) 141 54
Alpha-fetoprotein (ng/mL) 57.52 122.03
Histologic variables
Fibrosis stage
F0–1/ F2/ F3/ F4 44 (11.5)/93 (24.4)/
94 (24.7)/150 (39.4)
Activity grade
A0–2/ A3–4 167 (43.8)/214 (56.2)
Length of biopsy samples (mm) 24.5 11.8
Liver stiffness measurement
Liver stiffness (kPa) 13.9 10.2
Interquartile range (kPa) 1.9 1.7
Antiviral agents
Nucleos (t)ide analogs/
pegylated-interferon
344 (90.3)/37 (9.7)
Variables are expressed as meanSD or n (%).
Medicine  Volume 95, Number 12, March 2016Diagnostic Performances of TE and the Optimal
LS Cutoff for Each Fibrosis Stage
The optimal cutoff LS values and corresponding diagnos-
tic indexes of our study cohort were calculated (Supplementary
Table 1, http://links.lww.com/MD/A759). The AUCs of TE to
predict F2 (n¼ 337), F3 (n¼ 244), and F4 (n¼ 148)
fibrosis stage were 0.804 (05% CI 0.747–0.962), 0.830 (95%
CI 0.786–0.874), and 0.824 (95% CI 0.783–0.865), respect-
ively. The cutoff LS values for F2, F3, and F4 were 7.5 kPa
(sensitivity 79.5% specificity 65.9%), 9.5 kPa (sensitivity
76.6% specificity 80.3%), and 11.5 kPa (sensitivity 75.7%
specificity 79.0%), respectively.
HCC Development During Follow-Up
During a median follow-up period of 48.1 (IQR 30.3–
69.3) months, 34 (8.9%) patients experienced HCC develop-
ment. Furthermore, 36 (9.4%) patients experienced LRE devel-
opment (31 HCCs and 5 hepatic decompensations as the first
event). The cumulative incidence rates of HCC at 3, 5, and 7
years were 6.5%, 11.2%, and 11.9%, respectively, with an
annual incidence of 22 per 1000 person-years (Figure 1A).
HBeAg¼ hepatitis B e antigen; kPa¼ kilopascal.The cumulative incidence rates of LRE at 3, 5, and 7 years were
7.0%, 11.7%, 12.5%, respectively, with an annual incidence of
23 per 1000 person-years (Figure 1B).
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.Comparison of Baseline Characteristics of
Patients With and Without HCC and LRE
When the baseline characteristics of patients with and
without HCC were compared (Table 2), age (mean 54.5 vs.
43.0 years), proportion of diabetes mellitus (20.6 vs. 6.9%),
histological F4 fibrosis stage (70.6 vs. 35.7%), and LS value
(mean 20.0 vs. 13.3 kPa) were significantly higher in patients
with HCC development than in those without (all P<0.05),
whereas ALT level (52.4 vs. 140.5 IU/L) and platelet count (128
vs. 142 109/L) were significantly lower in patients with HCC
development than in those without (all P<0.05).
When the baseline characteristics of patients who experi-
enced an LRE were compared with those of patients who did not
(Table 2), age (mean 54.3 vs. 43.0 years), proportion of
hypertension (22.2 vs. 6.7%), histological F4 fibrosis stage
(72.2 vs. 35.4%), and LS value (21.3 vs. 13.2 kPa) were
significantly higher in patients with LRE development than
in those without (all P<0.05), whereas ALT level (52.3 vs.
141 IU/L), HBV-DNA level (5.63 vs. 6.21 log10 IU/mL), and
platelet count (129 vs. 142 109/L) were significantly lower in
patients with LRE development (all P<0.05).
Comparison of the Prognostic Performance of LS
Value and Histological Fibrosis Stage
The AUCs of the LS value and histological fibrosis stage
for HCC development at 3- and 5- years are shown in Table 3.
Although the AUC values of LS value to predict HCC devel-
opment at 3-years and 5-years were higher than those of
histological fibrosis stage, statistical significances were not
reached (all P>0.05). Similar results were obtained with
respect to LRE development (Table 3).
Independent Predictors of HCC and LRE
Development
Univariate and subsequent multivariate analysis to identify
independent predictors of HCC and LRE development are
described in Table 4. On univariate analysis, age, diabetes
mellitus, clinical cirrhosis, ALT level, fibrosis stage (F4 vs.
F0–3), and LS values significantly predicted HCC development
(all P<0.05), whereas age, diabetes mellitus, ALT level, serum
albumin level, alpha-fetoprotein, fibrosis stage (F4 vs. F0–3),
and LS values significantly predicted LRE development (all
P<0.05). On subsequent multivariate analyses, LS value was
an independent predictor of HCC development (P<0.001;
adjusted HR 1.042, 95% CI 1.016–1.070) and LRE develop-
ment (P¼ 0.006; adjusted HR 1.041, 95% CI 1.012–1.071),
together with age (Table 4), whereas histological fibrosis stage
was not an independent predictor for either HCC or LRE
development (all P>0.05). When LS value and histological
fibrosis stage were separately entered into multivariate analyses
to prevent statistical collinearity, LS value was selected as one
of the independent predictors of HCC (HR 1.058, 95% CI
1.020–1.097, P¼ 0.002) and LRE development (HR 1.052,
95% CI 1.018–1.087, P¼ 0.003) (Supplementary Table 2,
http://links.lww.com/MD/A759), whereas histological fibrosis
stage was not (P¼ 0.089 for HCC, P¼ 0.095 for LRE) (Supple-
mentary Table 3, http://links.lww.com/MD/A759).
Considering the independent prognostic significance of LS
values, we stratified our study population into 3 groups using
Prediction of HCC using TEthe cutoff LS values of 8.0 and 13 kPa according to the
stratifications used in several previous studies.15,17 The risk
of HCC and the risk of LRE development increased in
www.md-journal.com | 3
FIGURE 1. The cumulative incidence rates of HCC (A) and LRE (B) (Kaplan–Meier plot). The cumulative incidence rates of HCC at 3, 5, and
inci
spe
Seo et al Medicine  Volume 95, Number 12, March 2016association with higher LS values among 3 stratified groups
(log-rank test, all P<0.001) (Figure 2A and B). Although
histological fibrosis stage was not a significant predictor of
HCC and LRE development, when the patients were divided
into 3 groups according to histological fibrosis stage (F0-2, F3,
and F4), the risk of HCC and the risk of LRE development also
increased in association with higher histological fibrosis stage
(log-rank test, all P<0.001) (Figure 2C and D).
Association Between the Change in LS Values
and the Risk of Developing HCC or LRE
Of the study population, a second TE examination was
available at the time of VR after a median of 13.2 (range, 6.0–
24.0) months in 139 (36.5%) patients. We excluded 5 patients
who showed an increase in LS value from <13 kPa at baseline
to 13 kPa at follow-up to prevent statistical error caused by a
small sample size. The remaining patients were divided into 3
groups (group 1: n¼ 75, LS value <13 kPa at baseline and
follow-up; group 2: n¼ 33, LS value 13 kPa at baseline and
<13 kPa at follow-up; group 3: n¼ 26, LS values>13 kPa both
at baseline and follow-up). The cumulative incidence rates of
HCC and LRE differed significantly among the 3 groups (log-
rank test, all P<0.001) (Figure 3A and B).
DISCUSSION AND CONCLUSIONS
In this study, we aimed to evaluate whether TE, when
compared with histological data, can predict the risk of HCC
and LRE development in CHB patients starting antiviral
therapy. To our knowledge, this is the first Asian longitudinal
study with a relatively large sample size demonstrating that the
prognostic value of TE may be better than that of histological
information in assessing the risk of HCC and LRE development.
Our study also demonstrated that changes in LS values can
monitor the changing risk of HCC or LRE development during
antiviral therapy.
The results of our study address several important clinical
points. First, LB, as a gold standard, provide accurate infor-
mation regarding the degree of liver fibrosis and necroinflam-
mation, enable clinicians in determining whether to start
antiviral therapy, and provide prognostic information.9 Indeed,
7 years were 6.5%, 11.2%, and 11.9%, respectively, with an annual
of LREs at 3, 5, and 7 years were 7.0%, 11.7%, and 12.5%, re
HCC¼hepatocellular carcinoma; LRE¼ liver-related event.as shown in our study, histological assessment predicted the risk
of HCC and LRE development at 3- and 5-years of antiviral
therapy with acceptable accuracy (AUC around 0.75), which
4 | www.md-journal.comwas statistically similar to that of LS value. However, histo-
logical assessment was not selected as an independent predictor
of HCC and LRE development when adjusted with and without
LS value. In contrast, it was demonstrated that TE could assess
the fibrotic burden with acceptable accuracy (AUC more than
0.8 for each fibrosis stage) similar to a vast amount of previous
studies,13,19,25 and that TE was independently prognostic in
predicting HCC and LRE development even after adjusting for
LB and other variables. These findings support the necessity to
check LS values at the time of starting antiviral therapy. Our
findings also supported the use of TE to assess the changing risk
of HCC and LRE development. Because serial LBs are not
feasible in real clinical practice due to the inherent invasiveness
of biopsy, TE can be used to monitor the changes in LS values
during antiviral therapy.
Second, our study showed that the risk of developing HCC
or experiencing an LRE remained significant with cumulative
incidence rates of 11.2% and 11.7% at 5 year, respectively,
although it has been known that the risks significantly decreased
due to appropriate antiviral therapy.26,27 This supports the need
for risk prediction to assist prognostication and HCC surveil-
lance even with antiviral therapy. Although HBV DNA level
was one of the most important predictors of HCC development
in the era prior to antiviral therapy,28,29 the preexisting or
remained fibrotic burden after antiviral therapy has recently
received the attention as a significant prognostic candidate due
to diminished prognostic significance of HBV DNA by active
and potent antiviral therapy.7 In this regard, in the era of
antiviral therapy, the LS value, which can be used to assess
preexisting or residual fibrotic burden, may be a more appro-
priate risk prediction tool for HCC development. Accordingly,
recent studies demonstrated that the LS-based HCC risk scores
had better predictive performance than conventional scores in
CHB patients receiving antiviral therapy.17,30
In our study, a 1-point increase in LS value was associated
with a 1.041- and 1.040-fold increase in the risk of HCC and
LRE development, respectively. These results emphasize the
prognostic significance of LS values in determining the risk of
developing HCC in the era of antiviral therapy and are con-
sistent with the results of several previous studies with similar
clinical settings.18,19,31 A previous study by Kim et al19 demon-
dence of 22 per 1000 person-years. The cumulative incidence rates
ctively, with an annual incidence of 23 per 1000 person-years.strated that LS value was an independent predictor of LRE
development, whereas histological fibrosis stage was not, in
patients showing histologically advanced liver fibrosis and
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
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TABLE 3. Comparison of the Prognostic Performance of LS Value and Histological Fibrosis Stage
LS Value AUC (95% CI) Histological Fibrosis Stage AUC (95% CI) P Value
HCC development
At 3 yr 0.767 (0.684–0.849) 0.744 (0.669–0.820) 0.687
At 5 yr 0.745 (0.669–0.821) 0.744 (0.678–0.809) 0.914
LRE development
At 3 yr 0.782 (0.704–0.861) 0.752 (0.681–0.824) 0.888
At 5 yr 0.761 (0.687–0.834) 0.750 (0.687–0.813) 0.959
confi
Seo et al Medicine  Volume 95, Number 12, March 2016starting nucleot (s)ide analogs. Another study by Lee et al
demonstrated that LS values at complete VR are useful for
predicting LRE development in patients receiving entecavir.17
When we divided our study population into 3 groups using the
stratified LS value similar to the study by Lee et al, the risk of
developing HCC significantly increased in the groups with high
LS values. Similar to our study, prior studies have shown that
LS values significantly decreased in most CHB patients during
antiviral therapy, and those changes may reflect the changing
risk of HCC or LRE development during antiviral
therapy.17,24,32
AUC¼ area under the receiver operating characteristic curve; CI¼
event; LS¼ liver stiffness.Several issues still remained unresolved in our study. First,
the number of patients who developed HCC was small (8.9%),
which was related to the characteristics of our study population
TABLE 4. Independent Predictors of HCC or LRE Development
Univariate
Variables
P
Value
H
Demographic variables
Age (yr) <0.001 1.094
Male sex 0.702
Heavy alcohol consumption (vs. social and none) 0.232
Hypertension 0.419
Diabetes mellitus 0.015 0.913
Body mass index (kg/m2) 0.908
Clinical cirrhosis 0.026 0.830
Antiviral agents
Nucleos (t)ide analog (vs. pegylated interferon) 0.286
Entecavir and tenofovir (vs. others) 0.790
Laboratory variables
Alanine aminotransferase (IU/L) 0.023 0.995
Serum albumin (g/dL) 0.088
Total bilirubin (mg/dL) 0.737
HBeAg positivity 0.521
Log10 HBV DNA (IU/mL) 0.080
Platelet count (109/L) 0.115
Alpha-fetoprotein (ng/mL) 0.067
Histologic variables
Fibrosis stage F4 (vs. F0–3) 0.001 1.403
Liver stiffness measurement
Liver stiffness (kPa) <0.001 1.041
CI¼ confidence interval; HBeAg¼ hepatitis B e antigen; HCC¼ hepato
6 | www.md-journal.comreceiving antiviral therapy. Nevertheless, the homogeneity of
our population with respect to antiviral treatment, histological
data, and follow-up duration may have played a role in revealing
the clinical significance of TE. Second, if histological data had
been available at the time of VR, the association of LS change
with histological fibrosis change might have been more clearly
determined. A well-designed future study with follow-up histo-
logical data is required to confirm whether TE can monitor the
changes in the fibrotic burden during and after antiviral therapy.
Finally, after a rigorous review of the literature, we decided to
focus on the performance of TE instead of simple noninvasive
dence interval; HCC¼ hepatocellular carcinoma; LRE¼ liver-relatedmethods such as AST to platelet ratio index (APRI), FIB-4, and
Forn index. Despite being a good alternative to LB, TE is not
widely available due to its high cost, especially in resource-
HCC LRE
Multivariate Univariate Multivariate
azard Ratio
(95% CI)
P
Value
P
value
Hazard ratio
(95% CI) P value
(1.046–1.144) <0.001 <0.001 1.087 (1.041–1.135) <0.001
0.790
0.277
0.504
(0.367–2.269) 0.844 0.004 0.937 (0.383–2.292) 0.886
0.590
(0.389–1.770) 0.630
0.269
0.791
(0.987–1.002) 0.163 0.019 0.995 (0.988–1.002) 0.159
0.018 0.670 (0.295–1.522) 0.339
0.762
0.709
0.076
0.122
0.038 0.995 (0.985–1.005) 0.298
(0.600–3.284) 0.435 <0.001 1.237 (0.502–3.045) 0.644
(1.014–1.069) 0.003 <0.001 1.040 (1.011–1.071) 0.006
cellular carcinoma; kPa¼ kilopascal; LRE¼ liver-related events.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 2. The cumulative incidence rates of HCC based on stratified LS values (<8, 8–13, and >13 kPa) and histological fibrosis stage
(F0–2, F3, and F4) (A and B), and the cumulative incidence rates of LRE based on stratified LS values and histological fibrosis stage
(C and D). The cumulative incidence rates of HCC and LRE increased significantly in association with higher LS value and with higher
histological fibrosis stage (log-rank test, all P<0.001). HCC¼hepatocellular carcinoma; LRE¼ liver-related event.
FIGURE 3. The cumulative incidence rates of HCC (A) and LRE (B) according to the changes in LS values (n¼134). The overall incidence
rates of HCC and LRE differed significantly among the 3 groups (log-rank test, all P<0.001). HCC¼hepatocellular carcinoma; LRE¼ liver-
related event.
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32. Kim BK, Oh HJ, Park JY, et al. Early on-treatment change in liverlimited countries. Thus, future studies should focus on simple
noninvasive methods.
In conclusion, our study showed the predictive value of LS
measurement using TE, as compared with the histological
fibrosis stage, in predicting HCC and LRE development in
patients receiving antiviral therapy. Despite the reduction in
HCC and LRE risk attributable to effective antiviral therapy, the
risk remains substantial. Our study supports that tailored sur-
veillance strategies for HCC could be established based on LS
values. However, further investigation is needed to determine
whether the current surveillance strategy can be optimized
based on the LS value at the time of starting antiviral therapy.
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